Erectile Dysfunction (ED) is one of the most debilitating male sexual disorders characterized by the inability to attain or sustain an erection hard and long enough for sexual performance.
Most men suffer from this sexual disorder in silence. If left untreated, ED could increase the risk of physical as well as mental health issues. Usually, managing this sexual dysfunction included treating underlying medical conditions.
There are a few FDA-approved drugs available for the treatment of ED, such as sildenafil citrate (Viagra), tadalafil (Cialis), vardenafil (Levitra), avanafil (Stendra), among others. These drugs belong to a class of therapeutic agents called PDE5 (phosphodiesterase-5) inhibitors.
These ED drugs work by supplying enough blood to the penile organ during sexual stimulation so a user can experience a hard and long-lasting erection.
In 2018, the global erectile dysfunction market was more than $4117 million. It is estimated that the market would reach up to $4812.6 million by 2025 at a compound annual growth rate (CAGR) of 2.25%.
A sample report of global erectile dysfunction market size, growth, and forecast is available online on Trends Market Research.
In 2018, North America dominated the global erectile dysfunction market, with more than 42% of the total market share.
The factors that boost the overall growth of the market include better access to ED drugs and insurance coverage for penile implant surgeries.
Europe has so far been the second-largest market; however, Asia Pacific has been showing the fastest growth due to the rapidly changing healthcare sector and the increased number of opportunities in the market.
Africa has a minimum share in the global erectile dysfunction market because of the presence of the poor and slow developing nation. On the other hand, the Middle East has been holding the main share of the regional market because of its well-developed technology.
The global ED market is also growing due to factors such as disease awareness, patient education, and an increasing amount of patients willing to seek medical assistance for the management of erectile dysfunction.
Furthermore, the market is also growing due to the increasing demand for cheap generic ED drugs.
However, there are a few factors limiting the growth rate in some developing nations. Those factors include a rise in the risk of STDs, limited insurance coverage for ED drugs, availability of fake ED drugs, and social stigma.
In January 2017, Eli Lilly, which develops Cialis, was awarded as the world’s most ethical company. In June 2017, Pfizer, which developed the little blue pill Viagra, acquired AstraZeneca’s Neksium (esomeprazole), a heartburn medication.
